MediciNova, Inc. (NASDAQ:MNOV)’s stock price traded up 8.7% on Monday . The company traded as high as $9.18 and last traded at $9.10, 222,314 shares traded hands during mid-day trading. An increase of 123% from the average session volume of 99,562 shares. The stock had previously closed at $8.37.
Separately, BidaskClub cut MediciNova from a “sell” rating to a “strong sell” rating in a research report on Friday.
The business has a 50-day simple moving average of $9.31 and a two-hundred day simple moving average of $9.60. The company has a market cap of $353.36 million, a price-to-earnings ratio of -25.28 and a beta of 1.19.
MediciNova Company Profile (NASDAQ:MNOV)
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.
Featured Story: Gross Domestic Product (GDP)
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.